利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

206 条记录 (耗时 0.069 秒)

    Death domain containing receptor 5
    1.
    发明授权
    Death domain containing receptor 5 失效
    含有受体5的死亡域

    公开(公告)号：US07803615B1

    公开(公告)日：2010-09-28

    申请号：US09042583

    申请日：1998-03-17

    申请人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Jeffrey Y. Su ,  Craig A. Rosen

    发明人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Jeffrey Y. Su ,  Craig A. Rosen

    IPC分类号： C07K14/705 ,  C12N5/10 ,  C12N15/12 ,  C12N15/62 ,  C12N15/63

    CPC分类号： C07K14/7151 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族的成员的新的含有死亡域的受体-5（DR5）蛋白，现在已经显示结合TRAIL。 特别地，提供编码人DR5蛋白的分离的核酸分子。 还提供了DR5多肽，载体，宿主细胞以及用于制备它们的重组方法。 本发明还涉及用于鉴定DR5活性的拮抗剂和拮抗剂的筛选方法。

    Human Chemotactic Cytokine I Polypeptides
    2.
    发明申请
    Human Chemotactic Cytokine I Polypeptides 审中-公开
    人类趋化细胞因子I多肽

    公开(公告)号：US20090062510A1

    公开(公告)日：2009-03-05

    申请号：US11737622

    申请日：2007-04-19

    申请人： Jian Ni ,  Guo-Liang Yu ,  Pedro Alfonso ,  Reiner L. Gentz ,  Jeffrey Y. Su

    发明人： Jian Ni ,  Guo-Liang Yu ,  Pedro Alfonso ,  Reiner L. Gentz ,  Jeffrey Y. Su

    IPC分类号： C07K14/52

    CPC分类号： C07K14/52 ,  C07H21/04

    摘要： Human chemotactic cytokine I polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.

    摘要翻译： 公开了人类趋化性细胞因子I多肽和编码这种趋化性细胞因子的DNA（RNA）以及通过重组技术产生此类多肽的方法。 还公开了利用这种趋化性细胞因子治疗白血病，肿瘤，慢性感染，自身免疫疾病，纤维化病症，伤口愈合和牛皮癣的方法。 还公开了抗这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎，自身免疫，慢性和急性炎性和感染性疾病，过敏反应，前列腺素不依赖性发烧和骨髓衰竭的治疗剂的用途。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码趋化性细胞因子的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定。

    Death domain containing receptor 5
    3.
    发明授权
    Death domain containing receptor 5 有权
    含有受体5的死亡域

    公开(公告)号：US06743625B2

    公开(公告)日：2004-06-01

    申请号：US09874138

    申请日：2001-06-06

    申请人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    发明人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    IPC分类号： C07K14705

    CPC分类号： C07K14/7151 ,  A61K38/00 ,  A61K39/395 ,  C07K14/70578 ,  C07K2319/00 ,  C07K2319/30 ,  A61K2300/00

    摘要： The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族的成员的新的含有死亡域的受体-5（DR5）蛋白，现在已经显示结合TRAIL。 特别地，提供编码人DR5蛋白的分离的核酸分子。 还提供了DR5多肽，载体，宿主细胞以及用于制备它们的重组方法。 本发明还涉及用于鉴定DR5活性的拮抗剂和拮抗剂的筛选方法。

    Antibodies to human cystatin E
    4.
    发明授权
    Antibodies to human cystatin E 有权
    人类半胱氨酸蛋白酶抑制剂E的抗体

    公开(公告)号：US06300477B1

    公开(公告)日：2001-10-09

    申请号：US09241376

    申请日：1999-02-02

    申请人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    发明人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    IPC分类号： C07K1618

    CPC分类号： C07K14/8139 ,  A61K38/00

    摘要： Disclosed are antibodies and antibody fragments that bind to novel human CysE polypeptides. Also provided are methods for producing the antibodies. Also disclosed are methods for utilizing such antibodies and antibody fragments for the purification and analysis of CysE polypeptides, as well as the diagnosis and treatment of CysE polypeptide associated diseases.

    摘要翻译： 公开了结合新的人CysE多肽的抗体和抗体片段。 还提供了用于产生抗体的方法。 还公开了利用这些抗体和抗体片段来纯化和分析CysE多肽的方法，以及CysE多肽相关疾病的诊断和治疗。

    Death domain containing receptor 5
    6.
    发明申请
    Death domain containing receptor 5 审中-公开
    含有受体5的死亡域

    公开(公告)号：US20080248046A1

    公开(公告)日：2008-10-09

    申请号：US12010106

    申请日：2008-01-18

    申请人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    发明人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    IPC分类号： A61K39/395 ,  C12N5/06 ,  A61P35/00 ,  A61P31/12

    CPC分类号： C07K14/70578 ,  A61K38/00 ,  C07K16/2878 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/30

    摘要： The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and/or antagonists of DR5 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族的成员的新的含有死亡域的受体-5（DR5）蛋白，现在已经显示结合TRAIL。 特别地，提供编码人DR5蛋白的分离的核酸分子。 还提供了DR5多肽，载体，宿主细胞以及用于制备它们的重组方法。 本发明还涉及用于鉴定DR5活性的拮抗剂和拮抗剂的筛选方法。 本发明还涉及使用DR5特异性抗体（其可以是DR5活性的激动剂和/或拮抗剂）的减少或增加的细胞凋亡相关疾病的治疗。

    Human cystatin E polynucleotides
    7.
    发明授权
    Human cystatin E polynucleotides 失效
    人半胱氨酸蛋白酶抑制剂E多核苷酸

    公开(公告)号：US06617132B2

    公开(公告)日：2003-09-09

    申请号：US09940497

    申请日：2001-08-29

    申请人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    发明人： Jian Ni ,  Reiner L. Gentz ,  Guo-Liang Yu ,  Craig A. Rosen

    IPC分类号： C12N510

    CPC分类号： C07K14/8139 ,  A61K38/00

    摘要： Disclosed is a human CysE polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Also disclosed are methods for utilizing such polypeptide for treating osteoporosis, tumor metastases, microbial infections, viral infection, septic shock, inflammation, retinal irritation, caries, cachicia and muscle wasting. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.

    摘要翻译： 公开了编码这种多肽的人CysE多肽和DNA（RNA）。 还提供了通过重组技术产生这种多肽的方法。 还公开了利用这种多肽治疗骨质疏松症，肿瘤转移，微生物感染，病毒感染，败血性休克，炎症，视网膜刺激，龋齿，眼球和肌肉消瘦的方法。 还公开了用于检测编码序列中的突变和衍生自宿主的样品中多肽浓度变化的诊断方法。

    DR3 antibodies
    9.
    发明授权
    DR3 antibodies 失效
    DR3抗体

    公开(公告)号：US07708996B2

    公开(公告)日：2010-05-04

    申请号：US12046107

    申请日：2008-03-11

    申请人： Guo-Liang Yu ,  Jian Ni ,  Reiner L. Gentz ,  Patrick J. Dillon

    发明人： Guo-Liang Yu ,  Jian Ni ,  Reiner L. Gentz ,  Patrick J. Dillon

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K16/28

    CPC分类号： C07K14/4747 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  C07K14/70578 ,  C07K16/2878 ,  C07K2317/21 ,  C12N2799/026

    摘要： The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新型死亡域含有受体（DR3和DR3-V1）蛋白。 特别地，提供编码人DR3和DR3-V1蛋白的分离的核酸分子。 还提供DR3和DR3-V1多肽，载体，宿主细胞以及用于制备它们的重组方法也是如此。 还提供了结合本发明多肽的抗体及其片段。 本发明还涉及用于鉴定DR3和DR3-V1活性的激动剂和拮抗剂的筛选方法。

    Death domain containing receptors
    10.
    发明授权
    Death domain containing receptors 有权
    含有受体的死亡域

    公开(公告)号：US07357927B2

    公开(公告)日：2008-04-15

    申请号：US10189189

    申请日：2002-07-05

    申请人： Guo-Liang Yu ,  Jian Ni ,  Reiner L. Gentz ,  Patrick J. Dillon

    发明人： Guo-Liang Yu ,  Jian Ni ,  Reiner L. Gentz ,  Patrick J. Dillon

    IPC分类号： A61K39/395 ,  A61K39/00 ,  C07K16/18 ,  C07K16/28

    CPC分类号： C07K14/4747 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  C07K14/70578 ,  C07K16/2878 ,  C07K2317/21 ,  C12N2799/026

    摘要： The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

    摘要翻译： 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新型死亡域含有受体（DR3和DR3-V1）蛋白。 特别地，提供编码人DR3和DR3-V1蛋白的分离的核酸分子。 还提供DR3和DR3-V1多肽，载体，宿主细胞以及用于制备它们的重组方法也是如此。 还提供了结合本发明多肽的抗体及其片段。 本发明还涉及用于鉴定DR3和DR3-V1活性的激动剂和拮抗剂的筛选方法。